Scholarlink

Background <p>Triple-negative breast cancer (TNBC) lacks expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Genetic mutations, particularly in <i>BRCA1</i> and <i>BRCA2</i>, significantly influence its pathogenesis and clinical outcomes. This study evaluated the prevalence of <i>BRCA1</i> and <i>BRCA2</i> mutations in Turkish TNBC patients and investigated associated clinical, demographic, and pathological factors.</p> Materials and methods <p>Patients with TNBC who presented to the Cancer Genetics Department at Istanbul University Oncology Institute were included. Peripheral blood mononuclear cells were analyzed for <i>BRCA1</i> and <i>BRCA2</i> mutations using the Illumina MiSeq Next Generation Sequencing (NGS) platform. Patients were categorized as <i>BRCA1 +</i> or <i>BRCA2+</i> (mutation carriers) or <i>BRCA1-</i> or <i>BRCA2-</i> (mutation non-carriers). Comparative analyses were conducted to identify differences between groups, and clustering analysis examined mutation patterns.</p> Results <p>Among 485 TNBC patients, 119 (24.5%) carried pathogenic variants in <i>BRCA1</i> and/or <i>BRCA2</i> genes. Of these 119 carriers, 4 (0.8% of the total) harbored mutations in both genes. Specifically, 101 (20.8%) had <i>BRCA1 +</i> mutations, and 22 (4.5%) had <i>BRCA2 +</i> mutations. The carrier group had higher rates of bilateral breast cancer (BC) (14.3% vs. 4.9%), a family history of breast and ovarian cancer (BC and OC) (51.3% vs. 26%), and increased first-degree relative cancer cases. Bilateral BC was associated with a 2.748-fold increased risk of <i>BRCA1 +</i> mutations, while postmenopausal status reduced risk by 0.350-fold. Each additional first-degree BC case increased <i>BRCA1 +</i> mutation risk by 2.410-fold. Cluster analysis identified two distinct mutation patterns.</p> Conclusion <p>Turkish TNBC patients with <i>BRCA1 +</i> or <i>BRCA2 +</i> mutations exhibit unique clinical and familial characteristics, emphasizing the importance of genetic screening and familial risk evaluation in TNBC management. These findings underscore the clinical relevance of <i>BRCA</i> testing in TNBC patients for personalized screening and treatment strategies. Notably, this study provides the largest TNBC cohort (<i>n</i> = 485) reported from Türkiye, highlighting the significant role of <i>BRCA1</i> in TNBC pathogenesis and offering a roadmap for individualized management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetic risk and clinical implications of BRCA1 and BRCA2 mutations in Turkish triple-negative breast cancer patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月29日

查看全文
  • Betul Celik Demirbas,
  • Seda Kilic Erciyas,
  • Ozge Sukruoglu Erdogan,
  • Zubeyde Yalniz Kayim,
  • Ozge Pasin,
  • Merve Cigdem Ozgel,
  • Seref Bugra Tuncer

摘要

Background

Triple-negative breast cancer (TNBC) lacks expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Genetic mutations, particularly in BRCA1 and BRCA2, significantly influence its pathogenesis and clinical outcomes. This study evaluated the prevalence of BRCA1 and BRCA2 mutations in Turkish TNBC patients and investigated associated clinical, demographic, and pathological factors.

Materials and methods

Patients with TNBC who presented to the Cancer Genetics Department at Istanbul University Oncology Institute were included. Peripheral blood mononuclear cells were analyzed for BRCA1 and BRCA2 mutations using the Illumina MiSeq Next Generation Sequencing (NGS) platform. Patients were categorized as BRCA1 + or BRCA2+ (mutation carriers) or BRCA1- or BRCA2- (mutation non-carriers). Comparative analyses were conducted to identify differences between groups, and clustering analysis examined mutation patterns.

Results

Among 485 TNBC patients, 119 (24.5%) carried pathogenic variants in BRCA1 and/or BRCA2 genes. Of these 119 carriers, 4 (0.8% of the total) harbored mutations in both genes. Specifically, 101 (20.8%) had BRCA1 + mutations, and 22 (4.5%) had BRCA2 + mutations. The carrier group had higher rates of bilateral breast cancer (BC) (14.3% vs. 4.9%), a family history of breast and ovarian cancer (BC and OC) (51.3% vs. 26%), and increased first-degree relative cancer cases. Bilateral BC was associated with a 2.748-fold increased risk of BRCA1 + mutations, while postmenopausal status reduced risk by 0.350-fold. Each additional first-degree BC case increased BRCA1 + mutation risk by 2.410-fold. Cluster analysis identified two distinct mutation patterns.

Conclusion

Turkish TNBC patients with BRCA1 + or BRCA2 + mutations exhibit unique clinical and familial characteristics, emphasizing the importance of genetic screening and familial risk evaluation in TNBC management. These findings underscore the clinical relevance of BRCA testing in TNBC patients for personalized screening and treatment strategies. Notably, this study provides the largest TNBC cohort (n = 485) reported from Türkiye, highlighting the significant role of BRCA1 in TNBC pathogenesis and offering a roadmap for individualized management.